Aastrom Biosciences, a developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, has hired Scott Durbin as chief financial officer (CFO). Durbin brings more than 15 years of healthcare-related banking, financial and corporate development experience to Aastrom.
Durbin was formerly chief operating officer (COO) and CFO of Prescient Medical, which develops diagnostic and therapeutic catheter-based medical devices for the treatment of severe coronary artery disease. While at Prescient, Durbin raised more than US$60m in private equity financing and helped advance the company through early-stage research, development and regulatory approval. Previously, he served as a finance and corporate development consultant for Scios, a Johnson & Johnson subsidiary, and Alteon. Prior to this consulting work, he was an investment banker with Lehman Brothers, where he completed more than US$5bn in financings and merger and acquisition (M&A) transactions for life science companies.
Durbin earned an MPH in health management from the Yale University School of Medicine & School of Management and a BS from the University of Michigan.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.